Altered Expression of Endogenous Soluble Vascular Endothelial Growth Factor Receptor-2 Is Involved in the Progression of Esophageal Squamous Cell Carcinoma
Altered Expression of Endogenous Soluble Vascular Endothelial Growth Factor Receptor-2 Is Involved in the Progression of Esophageal Squamous Cell Carcinoma
复制标题
内源性可溶性血管内皮生长因子受体2表达的改变参与食管鳞状细胞癌的进展
DOI：
10.1369/0022155413480181
复制
发表时间：
2013-02
影响因子：
3.2
通讯作者：
Xu, Li-Yan
中科院分区：
文献类型：
--
作者：
Li, En-Min;Chen, Tao;Zhao, Qing;Huang, Jian-Hao;Chen, Jie-Xin;Zheng, Chun-Peng;Xu, Xiu-E;Wu, Jian-Yi;Xu, Li-Yan
内源性可溶性血管内皮生长因子受体-2 （esVEGFR-2）是一种新的VEGFR-2剪接变体，被证明是淋巴管生长的第一个内源性特异性抑制剂。esVEGFR-2在食管鳞状细胞癌（ESCC）中的表达及其临床病理作用尚不清楚。本文采用定量RT-PCR方法检测90对ESCC原发组织中esVEGFR-2和VEGF-C mRNA水平，并采用免疫组化染色法检测182例ESCC原发组织中esVEGFR-2蛋白水平。并分析esVEGFR-2表达与临床病理特征的相关性。与相应的非肿瘤性食管黏膜组织相比，esVEGFR-2 mRNA水平降低，VEGF-C mRNA水平升高。esVEGFR-2 mRNA水平下调与pTNM分期有显著相关性（χ2 = 7.790, p=0.02）。esVEGFR-2免疫组化染色在ESCC组织中有降低的趋势；esVEGFR-2蛋白较低表达与预后较好相关（χ2 = 6.366, p=0.012）， ESCC组织中esVEGFR-2蛋白较高积聚是患者生存不良的独立预后因素（风险比为1.606；95%可信区间为1.042-2.476;p=0.032）。综上所述，esVEGFR-2表达的改变与ESCC的进展相关。esVEGFR-2可能作为ESCC患者新的独立预后指标。
Endogenous soluble vascular endothelial growth factor receptor-2 (esVEGFR-2), a new splicing variant of VEGFR-2, was shown to be the first endogenous specific inhibitor of lymphatic vessel growth. The expression of esVEGFR-2 and its clinicopathological roles in esophageal squamous cell carcinoma (ESCC) are unclear. In this article, quantitative RT-PCR was employed to detect the mRNA levels of esVEGFR-2 and VEGF-C in 90 paired primary ESCC tissues, along with immunohistochemical staining to measure esVEGFR-2 protein in 182 ESCC primary tissues. Correlations between esVEGFR-2 expression and clinicopathological features were also analyzed. Compared with the corresponding non-neoplastic esophageal mucosa tissues, the mRNA level of esVEGFR-2 was decreased, whereas the mRNA level of VEGF-C was increased in ESCCs. Downregulation of esVEGFR-2 mRNA level was significantly correlated with pTNM stages (χ2 = 7.790, p=0.02). Immunohistochemical staining of esVEGFR-2 was inclined to be reduced in ESCC tissues; lower esVEGFR-2 protein expression was related to better prognosis (χ2 = 6.366, p=0.012), whereas higher esVEGFR-2 protein accumulation in ESCC tissues was an independent prognostic factor for poor survival of patients (hazard ratio, 1.606; 95% confidence interval, 1.042–2.476; p=0.032). Taken together, altered expression of esVEGFR-2 is correlated with progression of ESCC. esVEGFR-2 might serve as a new independent prognostic marker for ESCC patients.
登录
查看更多内容
影响因子：
2
作者：
S. Kuemmel;Anke Thomas;S. Landt;Andrea Fuger;P. Schmid;M. Kriner;J. Blohmer;J. Sehouli;Gerhard Sch
通讯作者：
S. Kuemmel;Anke Thomas;S. Landt;Andrea Fuger;P. Schmid;M. Kriner;J. Blohmer;J. Sehouli;Gerhard Sch
影响因子：
5.2
作者：
Pavlakovic H;Becker J;Albuquerque R;Wilting J;Ambati J
通讯作者：
Ambati J
影响因子：
11.5
作者：
Cui, Lei;Xu, Li-Yan;Li, En-Min
通讯作者：
Li, En-Min
DOI：
--
发表时间：
2009-12
期刊：
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
影响因子：
--
作者：
B. Kieć-Wilk;U. Raźny;J. Mathers;A. Dembińska-kieć
通讯作者：
B. Kieć-Wilk;U. Raźny;J. Mathers;A. Dembińska-kieć
影响因子：
9.3
作者：
Shibata MA;Ambati J;Shibata E;Albuquerque RJ;Morimoto J;Ito Y;Otsuki Y
通讯作者：
Otsuki Y